STAT+: Drugmakers lay out their legal arguments against Trump’s drug pricing experiments
Stat News • 2/24/2026
Summary
Drugmakers are presenting their legal arguments against Medicare's initiatives aimed at reducing drug prices in the U.S. These comments outline a potential roadmap for legal challenges that may arise in response to these pricing experiments.
Advertisement
Lindy Score Breakdown (V4.2)
50d
Age
1
Sources
from cluster
1206
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1206/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1206/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 50 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Pharmalittle: We’re reading about a pancreatic cancer pill, FDA rejecting a Replimune drug again, and more
Stat News • 2 days ago
STAT+: Hospitals roll out chatbots, looking to reclaim their role in patients’ health conversations
Stat News • 2 days ago
STAT+: FDA pressures drugmakers to report trial results
Stat News • 1 day ago
STAT+: FDA pushes drugmakers to report missing clinical trial results
Stat News • 2 days ago
STAT+: GSK advancing ovarian cancer drug mo-rez
Stat News • 2 days ago
STAT+: Spyre Therapeutics IBD drug shows promise in early trial
Stat News • 2 days ago
STAT+: AI could check millions of CT scans for heart risk. Who will pay for it?
Stat News • Today
STAT+: Pharmalittle: We’re reading about FDA seeking more data on a Lilly obesity pill, a pharma 340B win, and more
Stat News • Today
STAT+: A $15 AI test, Project Glasswing, and how Doctronic pilot blindsided Utah medical board
Stat News • Today
STAT+: New Bain biotech startup, building on BMS drugs, gets a name and a CEO
Stat News • Today
